Case Study: Isolated Patella Lesion Repair with Knee Cartilage Repair Surgery
Important Safety Information
Full Prescribing Information
Cartilage Repair Blog
Go to Patient Site
Go to Patient Site
Back

Case Study: Isolated Patella Lesion Repair with Knee Cartilage Repair Surgery

Click to Find a MACI Representative in Your Area 

See a recent case study to learn how a 38-year-old runner was able to resume her active lifestyle following isolated patella lesion repair with MACI knee cartilage repair.

The Patient

  • 38-year-old female patient
  • Runner
  • BMI 23
  • 2 years of knee pain
  • Goal–Return to running

Patient’s Knee History

  • Exercise, stairs, bending caused pain
  • Recurrent injury over 2 years
  • Pain frequency 8
  • Prior treatment includes injections and physical therapy

Arthroscopy findings from a 38-year-old patient revealing 2.5 x 2.5 cm ICRS Grade 3 patella lesion inferior pole.

Diagnosis

  • Arthroscopy revealed 2.5 x 2.5 cm ICRS
  • Grade 2 patella lesion inferior pole

Surgical Approach

  • Lateral subvastus
  • Evert patella
  • Template: 2.5cm2 patella
  • 6-0 Vicryl stabilize graft
  • Micro-anchors inferiorly (reloaded with 5-0 Vicryl suture)

Rehab

  • POD # 3
  • 3/10 at 1st visit at 2 weeks post-op
  • CPM -10-20°increasing slowly 6-8 hours 4 week with goal Flexion 120° by 6 weeks
  • TTWB - 25% WB at 2 weeks, 50% WB at 2-4 weeks and then full WBAT 4-6 weeks
    • Immobilizer locked in extension with gait
  • 8-12 weeks:
    • CORE program
    • Limited open-chain exercises at 3 months and full allowed after 4 months

Learn more about MACI defect types and how the procedure can be used to treat multiple areas of the knee here.

Individual results may vary.

 

Please see below for full indication and ISI. Blog posts are intended to provide educational information only and do not constitute medical advice.

Back
Find a MACI rep icon

To learn more about MACI, contact a representative.

Find a MACI Rep 

#
Play icon

Watch live MACI case videos with notable orthopedic surgeons.

See technique videos 

Indication and Important Safety Information

Important Safety Information

Contraindications: MACI is contraindicated in patients with a known history of hypersensitivity to gentamicin, other aminoglycosides, products of porcine or bovine origin; in patients with severe osteoarthritis of the knee, inflammatory arthritis, inflammatory joint disease, or uncorrected congenital blood coagulation disorders; in patients who have undergone prior knee surgery in the past 6 months, excluding surgery to procure a biopsy or a concomitant procedure to prepare the knee for a MACI implant; or in patients unable to cooperate with a physician-prescribed post-surgical rehabilitation program.

Warnings and Precautions:
  • Malignancy: The risk of MACI in patients with malignancy in the area of cartilage biopsy or implant is unknown. Expansion of malignant or dysplastic cells present in biopsy tissue during manufacture and subsequent implantation may be possible.
  • Transmissible infectious diseases: Because patients undergoing procedures associated with MACI are not routinely tested for transmissible infectious diseases, cartilage biopsy and MACI implant may carry risk of transmitting infectious diseases.
  • Presurgical Comorbidities: Local inflammation or active infection in the bone, joint, and surrounding soft tissue, meniscal pathology, cruciate ligament instability, and misalignment should be assessed and treated prior to or concurrent with MACI implantation.
  • Product Sterility: Final sterility test results are not available at the time of shipping.

Adverse Reactions: The most frequently occurring adverse reactions reported for MACI (≥5%) were arthralgia, tendonitis, back pain, joint swelling, and joint effusion. Serious adverse reactions reported for MACI were arthralgia, cartilage injury, meniscus injury, treatment failure, and osteoarthritis.

Specific Populations:
  • Use of MACI in pediatric patients (younger than 18 years of age) or in patients over 65 years of age has not been established.
  • The MACI implant is not recommended during pregnancy. For implantations post-pregnancy, the safety of breastfeeding to an infant has not been determined.

To report negative side effects, contact Vericel Corporation at 1-800-453-6948 or FDA at 1-800-FDA-1088 (1-800-332-1088) or www.fda.gov/medwatch.

Please see Full Prescribing Information.

Indication

MACI® is an autologous cellularized scaffold product indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the knee with or without bone involvement in adults.

MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the knee with or without bone involvement in adults.

Limitations of Use

Effectiveness of MACI in joints other than the knee has not been established.

Safety and effectiveness of MACI in patients over the age of 55 years have not been established.